Antibiotics and methods of using same

Patent metadata

Field	Value
Publication number	US-10654852-B2
Application number	US-201716342903-A
Country	US
Kind code	B2
Filing date	Oct 20, 2017
Priority date	Oct 21, 2016
Publication date	May 19, 2020
Grant date	May 19, 2020

Abstract

The present invention includes novel 3,6-diazabicyclo[3.1.1]heptane antibiotic compounds and any salts or solvates thereof. The present invention further includes methods of preparing such compounds, and methods of treating bacterial infection in a subject using such compounds.

First claim

What is claimed is:

1. A compound for treating bacterial infections having the structure of formula (I):

wherein A is N or CR 7 ;
R 1 is hydrogen or C 1-5 linear or branched alkyl;
R 7 is independently hydrogen, C 1-5 linear or branched alkyl, or F; and
R 2 -R 6 are independently selected at each occurrence from hydrogen, —X, -L 1 -X, or -L 1 -R;
where
—X is independently selected at each occurrence from —CN, —N(R) 2 , or —F;
L 1 is selected independently at each occurrence from —NH—, —N(R)—, —C(O)—, —(CH 2 ) 1-4 —, —C(O)—N(R)—, —(C(R) 2 ) 1-3 —N(R)—, or —(C(R) 2 ) 1-3 —;
R is independently selected at each occurrence from hydrogen, or C 1-5 linear or branched alkyl;
wherein at least one of R 2 -R 4 is a group -L 1 -R;
or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 , wherein R is independently selected at each occurrence from hydrogen, methyl, or ethyl.

3. The compound according to claim 1 , wherein only one of R 2 -R 6 is -L 1 -R or -L 1 -X.

4. The compound according to claim 1 , wherein R 1 is hydrogen or methyl.

5. The compound according to claim 1 , wherein R 2 is -L 1 -R or -L 1 -X.

6. The compound according to claim 1 , wherein R 3 or R 4 is -L 1 -R or -L 1 -X.

7. The compound according to claim 1 , wherein —X is —NH 2 or —N(R) 2 .

8. The compound according to claim 1 , wherein R 3 -R 6 are independently selected at each occurrence from hydrogen, —CN, or —F.

9. The compound according to claim 1 having the structure

or a pharmaceutically acceptable salt thereof.

Assignees

• Broad Inst Inc

Inventors

• Vacca Joseph P

Classifications

• C07D471/08 Primary

  Bridged systems · CPC title

• A61K31/439 Primary

  the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46) · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61K31/4427

  containing further heterocyclic ring systems · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title